If you need more lookups,
subscriptions start at $34 USD/month.
Eduardo Rodenas Location
Carlisle, MA, US
Eduardo Rodenas Work
2013 -now Medical Director @
2011 -2013 Medical Lead @
2008 -2011 Sr. Medical Director @ Infinity Pharmaceuticals
1990 -2009 Group Director @ BMS
1992 -2008 Group Director Regulatory Affairs @ Bristol-Myers Squibb
Eduardo Rodenas Education
Facultad de Medicina Universidad Complutense
Doctor of Medicine (M.D.) (Internal Medicine Residency Program)
1978-1985
Eduardo Rodenas Skills
Pharmaceutical Industry
Oncology
Clinical Development
Clinical Trials
Drug Development
Pharmacovigilance
Medical Affairs
Regulatory Affairs
GCP
CTMS
Therapeutic Areas
Medical Writing
Regulatory Submissions
CRO
Medicine
Infectious Diseases
Diabetes
Neurology
Rheumatology
ICH-GCP
Market Access
Vaccines
Endocrinology
Pharmacology
Hematology
Biopharmaceuticals
Clinical Pharmacology
Health Economics
Translational Medicine
IND
Cardiology
Clinical Operations
Clinical Monitoring
Biotechnology
Drug Safety
Biomarkers
Neuroscience
Immunology
Protocol
Clinical Research
Lifesciences
Clinical Study Design
Pharmaceutical Sales
Biologics
Pharmaceutics
Hospital Sales
Cancer
Life Sciences
FDA
SOP
Development
Team Building
Customer Relations
Ich Gcp
Gastroenterology
Process Improvement
Strategic Planning
Operations
Drug Discovery
Clinical
Pharmaceuticals
Customer Service
EDC
Coaching
Project Management
Eduardo Rodenas Summary
Eduardo Rodenas, based in Carlisle, MA, US, is currently a Medical Director at Purdue Pharma. Eduardo Rodenas brings experience from previous roles at Purdue Pharma, Infinity Pharmaceuticals, BMS and Bristol-Myers Squibb. Eduardo Rodenas holds a 1978 - 1985 Doctor of Medicine (M.D.) in Internal Medicine Residency Program @ Facultad de Medicina Universidad Complutense. With a robust skill set that includes Pharmaceutical Industry, Oncology, Clinical Development, Clinical Trials, Drug Development and more. Eduardo Rodenas has 2 emails on RocketReach.
Looking for a different Eduardo Rodenas?
Find contact details for 700 million professionals.